Outlook Therapeutics
Lauren Nelson is currently serving as the Executive Director, Patient Access & Marketing at Outlook Therapeutics, Inc. Previously, Lauren held positions such as Senior Director, Market Access at Albireo Pharma, Inc., and Director, National Accounts for Zolgensma at Novartis Gene Therapies. Lauren has also worked with companies like Sanofi Genzyme, inVentiv, Biogen Idec, Takeda Pharmaceuticals, and Human Genome Sciences, gaining experience in various aspects of market access, account management, and preclinical development. Lauren holds a Master's degree in Biotechnology from The Johns Hopkins University and a Bachelor's degree in Biology and Studio Art from the University of Virginia.
This person is not in any offices
Outlook Therapeutics
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.